DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Imdur (Isosorbide Mononitrate) - Indications and Dosage

 
 



INDICATIONS AND USAGE

IMDUR Tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.

DOSAGE AND ADMINISTRATION

The recommended starting dose of IMDUR Tablets is 30 mg (given as a single 30 mg tablet or as 1/2 of a 60 mg tablet) or 60 mg (given as a single tablet) once daily. After several days, the dosage may be increased to 120 mg (given as a single 120 mg tablet or as two 60 mg tablets) once daily. Rarely, 240 mg may be required. The daily dose of IMDUR Tablets should be taken in the morning on arising. IMDUR Extended Release Tablets should not be chewed or crushed and should be swallowed together with a half-glassful of fluid. Do not break the 30 mg tablet.

HOW SUPPLIED

IMDUR Extended Release Tablets 30 mg are white, capsule-shaped tablets scored on one side and engraved "IMDUR" on the unscored side. They are supplied as follows:

Bottles of 100 NDC 0085-1374-01

IMDUR Extended Release Tablets 60 mg are white, capsule-shaped tablets scored on one side with "60-60" and engraved "IMDUR" on the unscored side. They are supplied as follows:

Bottles of 100 NDC 0085-2028-01

IMDUR Extended Release Tablets 120 mg are white, capsule-shaped tablets engraved "IMDUR" on one side and "120" on the other side. They are supplied as follows:

Bottles of 100 NDC 0085-0091-01

Store at controlled room temperature 20°-25°C (68°-77°F) [See USP].

IMDUR®
(isoserbide mononitrate)
Extended Release Tablets

Copyright © 1993, 2006 Schering Corporation, a subsidiary of Merck & Co., Inc. All rights reserved.

Rev. 12/10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017